154 related articles for article (PubMed ID: 37837240)
21. Preoperative Intensified Chemoradiation with Intensity-Modulated Radiotherapy and Simultaneous Integrated Boost Combined with Capecitabine in Locally Advanced Rectal Cancer: Long-Term Outcomes of a Real-Life Multicenter Study.
Lupattelli M; Palazzari E; Polesel J; Chiloiro G; Angelicone I; Panni V; Caravatta L; Di Biase S; Macchia G; Niespolo RM; Franco P; Epifani V; Meldolesi E; de Giacomo F; Lucarelli M; Montesi G; Mantello G; Innocente R; Osti MF; Gambacorta MA; Aristei C; De Paoli A
Cancers (Basel); 2023 Dec; 15(23):. PubMed ID: 38067405
[TBL] [Abstract][Full Text] [Related]
22. Salvage Surgery With Organ Preservation for Patients With Local Regrowth After Watch and Wait: Is It Still Possible?
Fernandez LM; Figueiredo NL; Habr-Gama A; São Julião GP; Vieira P; Vailati BB; Nasir I; Parés O; Santiago I; Castillo-Martin M; Carvalho C; Parvaiz A; Perez RO
Dis Colon Rectum; 2020 Aug; 63(8):1053-1062. PubMed ID: 32692070
[TBL] [Abstract][Full Text] [Related]
23. STAR-TREC: An International Three-arm Multicentre, Partially Randomised Controlled Trial Incorporating an External Pilot.
Bach SP
Clin Oncol (R Coll Radiol); 2023 Feb; 35(2):e107-e109. PubMed ID: 36577551
[TBL] [Abstract][Full Text] [Related]
24. [Total neoadjuvant therapy followed by watch and wait approach or organ preservation for MRI stratified low-risk rectal cancer: early result from a prospective, single arm trial].
Wang L; Zhao YM; Sun TT; Xu YL; Li SJ; Zhang XY; Cai Y; Li YH; Li ZW; Chen PJ; Peng YF; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):258-265. PubMed ID: 32192305
[No Abstract] [Full Text] [Related]
25. Non-inferiority multicenter prospective randomized controlled study of rectal cancer T
Serra-Aracil X; Pericay C; Golda T; Mora L; Targarona E; Delgado S; Reina A; Vallribera F; Enriquez-Navascues JM; Serra-Pla S; Garcia-Pacheco JC;
Int J Colorectal Dis; 2018 Feb; 33(2):241-249. PubMed ID: 29234923
[TBL] [Abstract][Full Text] [Related]
26. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial.
Rullier E; Rouanet P; Tuech JJ; Valverde A; Lelong B; Rivoire M; Faucheron JL; Jafari M; Portier G; Meunier B; Sileznieff I; Prudhomme M; Marchal F; Pocard M; Pezet D; Rullier A; Vendrely V; Denost Q; Asselineau J; Doussau A
Lancet; 2017 Jul; 390(10093):469-479. PubMed ID: 28601342
[TBL] [Abstract][Full Text] [Related]
27. Intentional Watch and Wait or Organ Preservation Surgery Following Neoadjuvant Chemoradiotherapy Plus Consolidation CAPEOX for MRI-defined Low-risk Rectal Cancer: Findings From a Prospective Phase 2 Trial (PKUCH-R01 Trial, NCT02860234).
Wang L; Zhang XY; Zhao YM; Li SJ; Li ZW; Sun YS; Wang WH; Wu AW;
Ann Surg; 2023 Apr; 277(4):647-654. PubMed ID: 35766394
[TBL] [Abstract][Full Text] [Related]
28. Organ or sphincter preservation for rectal cancer. The role of contact X-ray brachytherapy in a monocentric series of 112 patients.
Frin AC; Evesque L; Gal J; Benezery K; François E; Gugenheim J; Benizri E; Château Y; Marcié S; Doyen J; Gérard JP
Eur J Cancer; 2017 Feb; 72():124-136. PubMed ID: 28027515
[TBL] [Abstract][Full Text] [Related]
29. Factors that influence the adequacy of total mesorectal excision for rectal cancer.
Jeyarajah S; Sutton CD; Miller AS; Hemingway D;
Colorectal Dis; 2007 Nov; 9(9):808-15. PubMed ID: 17441969
[TBL] [Abstract][Full Text] [Related]
30. Role of radiotherapy in the treatment of rectal cancer in older patients.
Myint AS; Gérard JP
Eur J Surg Oncol; 2020 Mar; 46(3):349-357. PubMed ID: 31926607
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
[TBL] [Abstract][Full Text] [Related]
32. Organ preservation with local excision or active surveillance following chemoradiotherapy for rectal cancer.
Creavin B; Ryan E; Martin ST; Hanly A; O'Connell PR; Sheahan K; Winter DC
Br J Cancer; 2017 Jan; 116(2):169-174. PubMed ID: 27997526
[TBL] [Abstract][Full Text] [Related]
33. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcomes by a transanal approach to total mesorectal excision for rectal cancer.
Marks JH; Myers EA; Zeger EL; Denittis AS; Gummadi M; Marks GJ
Surg Endosc; 2017 Dec; 31(12):5248-5257. PubMed ID: 28643051
[TBL] [Abstract][Full Text] [Related]
35. Rectal Sparing Approach After Neoadjuvant Therapy in Patients with Rectal Cancer: The Preliminary Results of the ReSARCh Trial.
Marchegiani F; Palatucci V; Capelli G; Guerrieri M; Belluco C; Rega D; Morpurgo E; Coco C; Restivo A; De Franciscis S; Aschele C; Perin A; Bonomo M; Muratore A; Spinelli A; Ramuscello S; Bergamo F; Montesi G; Spolverato G; Del Bianco P; Gambacorta MA; Delrio P; Pucciarelli S
Ann Surg Oncol; 2022 Mar; 29(3):1880-1889. PubMed ID: 34855063
[TBL] [Abstract][Full Text] [Related]
36. Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial.
Verweij ME; Tanaka MD; Kensen CM; van der Heide UA; Marijnen CAM; Janssen T; Vijlbrief T; van Grevenstein WMU; Moons LMG; Koopman M; Lacle MM; Braat MNGJA; Chalabi M; Maas M; Huibregtse IL; Snaebjornsson P; Grotenhuis BA; Fijneman R; Consten E; Pronk A; Smits AB; Heikens JT; Eijkelenkamp H; Elias SG; Verkooijen HM; Schoenmakers MMC; Meijer GJ; Intven M; Peters FP
BMJ Open; 2023 Jun; 13(6):e065010. PubMed ID: 37321815
[TBL] [Abstract][Full Text] [Related]
37. Clinical response assessment after contact X-Ray brachytherapy and chemoradiotherapy for organ preservation in rectal cancer T2-T3 M0: The time/dose factor influence.
Benezery K; Montagne L; Evesque L; Schiappa R; Hannoun-Levi JM; Francois E; Thamphya B; Gerard JP
Clin Transl Radiat Oncol; 2020 Sep; 24():92-98. PubMed ID: 32695890
[TBL] [Abstract][Full Text] [Related]
38. Total neoadjuvant therapy followed by a watch-and-wait strategy for patients with rectal cancer (TOWARd): protocol for single-arm phase II/III confirmatory trial (JCOG2010).
Hashimoto T; Tsukamoto S; Murofushi K; Ito Y; Hirano H; Tsukada Y; Sasaki K; Mizusawa J; Fukuda H; Takashima A; Kanemitsu Y
BJS Open; 2023 Nov; 7(6):. PubMed ID: 37931233
[TBL] [Abstract][Full Text] [Related]
39. Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial).
Akiyoshi T; Shinozaki E; Taguchi S; Chino A; Hiratsuka M; Tominaga T; Nonaka T; Toda S; Matoba S; Matsui S; Okabayashi K; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Yamaguchi K; Ueno M; Kuroyanagi H; Fukunaga Y; Ishizuka N; Konishi T;
BMJ Open; 2022 Mar; 12(3):e055140. PubMed ID: 35304396
[TBL] [Abstract][Full Text] [Related]
40. Individualizing surgical treatment based on tumour response following neoadjuvant therapy in T4 primary rectal cancer.
Denost Q; Kontovounisios C; Rasheed S; Chevalier R; Brasio R; Capdepont M; Rullier E; Tekkis PP
Eur J Surg Oncol; 2017 Jan; 43(1):92-99. PubMed ID: 27717529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
